Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.cmi.2021.11.010
Title: Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study
Authors: Chia, PY
Ong, SWX
Chiew, CJ
Ang, LW
Chavatte, JM
Mak, TM
Cui, L 
Kalimuddin, S 
Chia, WN 
Tan, CW 
Chai, LYA 
Tan, SY
Zheng, S 
Lin, RTP 
Wang, L 
Leo, YS 
Lee, VJ 
Lye, DC 
Young, BE
Keywords: Breakthrough infection
COVID-19
Delta
SARS-CoV-2
Vaccination
Vaccine breakthrough
Variants of concern
COVID-19
COVID-19 Vaccines
Cohort Studies
Humans
Kinetics
Pandemics
Retrospective Studies
SARS-CoV-2
Vaccination
Vaccines, Synthetic
mRNA Vaccines
Issue Date: 1-Apr-2022
Publisher: Elsevier BV
Citation: Chia, PY, Ong, SWX, Chiew, CJ, Ang, LW, Chavatte, JM, Mak, TM, Cui, L, Kalimuddin, S, Chia, WN, Tan, CW, Chai, LYA, Tan, SY, Zheng, S, Lin, RTP, Wang, L, Leo, YS, Lee, VJ, Lye, DC, Young, BE (2022-04-01). Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clinical Microbiology and Infection 28 (4) : 612.e1-612.e7. ScholarBank@NUS Repository. https://doi.org/10.1016/j.cmi.2021.11.010
Abstract: Objectives: Highly effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed but variants of concerns are worrisome, especially B.1.617.2 (Delta) which has rapidly spread across the world. We aim to study if vaccination alters virological and serological kinetics in breakthrough infections. Methods: We conducted a multicentre retrospective cohort study of patients in Singapore who had received a licensed mRNA vaccine and been admitted to hospital with B.1.617.2 SARS-CoV-2 infection. We compared clinical features, virological and serological kinetics (anti-nucleocapsid, anti-spike and surrogate virus neutralization titres) between fully vaccinated and unvaccinated individuals. Results: Out of 218 individuals with B.1.617.2 infection, 84 received an mRNA vaccine of which 71 were fully vaccinated, 130 were unvaccinated and four received a non-mRNA vaccine. Despite significantly older age in the vaccine breakthrough group, only 2.8% (2/71) developed severe COVID-19 requiring oxygen supplementation compared with 53.1% (69/130) in the unvaccinated group (p < 0.001). Odds of severe COVID-19 following vaccination were significantly lower (adjusted odds ratio 0.07 95% CI 0.015–0.335, p 0.001). PCR cycle threshold values were similar between vaccinated and unvaccinated groups at diagnosis, but viral loads decreased faster in vaccinated individuals. Early, robust boosting of anti-spike protein antibodies was observed in vaccinated patients; however, these titres were significantly lower against B.1.617.2 than the wildtype vaccine strain. Discussion: The mRNA vaccines are highly effective at preventing symptomatic and severe COVID-19 associated with B.1.617.2 infection. Vaccination is associated with faster decline in viral RNA load and a robust serological response. Vaccination remains a key strategy for control of the COVID-19 pandemic.
Source Title: Clinical Microbiology and Infection
URI: https://scholarbank.nus.edu.sg/handle/10635/228436
ISSN: 1198743X
14690691
DOI: 10.1016/j.cmi.2021.11.010
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections a multicentre cohort study.pdfPublished version1.21 MBAdobe PDF

CLOSED

None

SCOPUSTM   
Citations

75
checked on Jan 26, 2023

Page view(s)

66
checked on Feb 2, 2023

Download(s)

1
checked on Feb 2, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.